Business
Renegotiation of Debt Facilit
Renegotiation of Debt Facilit.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n RNS Number : 2088P Allergy Therapeutics PLC 20 March 2009 \n \nReplacing RNS No: 2069P - wording amended\n\nFriday 20 March 2009\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n\nRenegotiation of Debt Facilities\n\nAllergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that it is in discussions with its bankers with the aim of renegotiating its debt facilities. The discussions are progressing well and the company is confident that they will be resolved swiftly. The company will make a further announcement in due course.\n\nFor further information\n\n\n\n\n\nAllergy Therapeutics\n\n\n+44 (0) 1903 845 820\n\n\n\n\nKeith Carter, Chief Executive\n\n\n \n\n\n\n\nIan Postlethwaite, Finance Director\n\n\n \n\n\n\n\nwww.allergytherapeutics.com\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nNomura Code Securities\n\n\n+44 (0) 207 776 1200\n\n\n\n\nJuliet Thompson\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nFinancial Dynamics\n\n\n+44 (0) 207 831 3113\n\n\n\n\nDavid Yates\n\n\n \n\n\n\n\nBen Brewerton\n\n\n \n\n\n\n\n\n\n\nAbout Allergy Therapeutics\n\nAllergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable core business achieving sales of allergy vaccines of £31 million in Germany, Italy, Spain and other EU markets through its own sales and marketing infrastructure. The Company is expanding its infrastructure with operations also in the United Kingdom, Poland, the Czech Republic, Slovakia and Austria.\nThis information is provided by RNSThe company news service from the London Stock Exchange END MSCBBGDXCGDGGCG\n ","length":5024,"tagName":"div"}]